Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials
Autor: | Davids, Matthew S., Sharman, Jeff P., Ghia, Paolo, Woyach, Jennifer A., Eyre, Toby A., Jurczak, Wojciech, Siddiqi, Tanya, Miranda, Paulo, Shahkarami, Mina, Butturini, Anna, Emeribe, Ugochinyere, Byrd, John C. |
---|---|
Zdroj: | In Blood Advances 9 July 2024 8(13):3345-3359 |
Databáze: | ScienceDirect |
Externí odkaz: |